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OBJECTIVE: To evaluate the influence of estrogen therapy and estrogen-progestin therapy on homocysteine
and C-reactive protein levels in postmenopausal women.
METHODS: In total, 99 postmenopausal women were included in this double-blind, randomized clinical trial
and divided into three groups: Group A used estrogen therapy alone (2.0 mg of 17b-estradiol), Group B
received estrogen-progestin therapy (2.0 mg of 17 b-estradiol +1.0 mg of norethisterone acetate) and Group C
received a placebo (control). The length of treatment was six months. Serum measurements of homocysteine
and C-reactive protein were carried out prior to the onset of treatment and following six months of therapy.
RESULTS: After six months of treatment, there was a 20.7% reduction in homocysteine levels and a 100.5%
increase in C-reactive protein levels in the group of women who used estrogen therapy. With respect to the
estrogen-progestin group, there was a 12.2% decrease in homocysteine levels and a 93.5% increase in C-
reactive protein levels.
CONCLUSION: Our data suggested that hormone therapy (unopposed estrogen or estrogen associated with
progestin) may have a positive influence on decreasing cardiovascular risk due to a significant reduction in
homocysteine levels.
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& INTRODUCTION
It is estimated that 25 million women reach menopause
each year. Worldwide, there are currently approximately
470 million women over 50 years of age. Data from
the World Health Organization show that in 20
years’ time, women will live half of their lifespan
postmenopause (1).
Cardiovascular disease is the greatest cause of death in
industrialized nations and is a problem in developing
countries, such as Brazil (2,3). Evidence that estrogen
therapy may have a protective effect on the cardiovascular
systems of postmenopausal women, reducing morbidity
and mortality from cardiovascular disease, was based on
various observational studies, such as the ‘‘Lipid Research
Clinics Study’’ (4). However, according to Barret-Connor
(5), the interpretation of data derived from observational
studies should be undertaken cautiously because the
possibility of distortions is great. Therefore, to determine
the possible benefit of estrogen and estrogen-progestin
therapy in reducing ischemic cardiac disease-related mor-
tality, interventional, prospective, randomized, placebo-
controlled studies should be carried out in a large number
of patients over an extended period of time (6-10).
The results of interventional studies are also discordant,
raising doubts regarding the real benefits of substitutive
hormone therapy (HT) in terms of either the primary or
secondary prevention of cardiovascular disease postmeno-
pause (7). With respect to secondary prevention, three
interventional studies, ‘‘Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart
disease in postmenopausal women’’ (HERS), ‘‘A clinical
trial of estrogen-replacement therapy after ischemic stroke’’
(ERA) and ‘‘Effects of estrogen replacement on the progres-
sion of coronary-artery atherosclerosis’’ (WEST), failed
to show that postmenopausal HT was able to prevent
cardiovascular disease (8-10). The results of the ‘‘Women’s
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Health Initiative’’ (WHI) study provoked discussions
regarding the action of HT in the prevention of cardiovas-
cular disease and raised doubts with respect to pre-
established concepts regarding the primary prevention of
these diseases(6,11). However, the cardiovascular risk
associated with unopposed estrogen may be lower than
that associated with a progestogen-estrogen combination
(12).
Because ischemic cardiovascular disease can surprise
women who have no traditional risk factors for the
condition, it is important to identify markers that are able
to predict the risk of developing atherothrombotic disease
(13,14). Studies have therefore been undertaken to find
markers that are predictive of the development of cardio-
vascular events, among which are homocysteine and C-
reactive protein (CRP) (13-15).
Homocysteine is a derivative of methionine, an essential
amino acid that is present in meat and dairy products.
Homocysteine is re-methylated into methionine through the
action of folic acid and vitamins B6 and B12 (15). Increased
levels of homocysteine are unfavorably associated with
coagulation function and with the vasodilatory and antith-
rombotic action of nitric oxide, thereby increasing the risk of
thrombosis and acute myocardial infarction (16). After
menopause, the serum levels of homocysteine are higher
than those in younger women. Certain investigators have
reported that substitutive HT significantly reduces these
levels (17).
CRP is a sensitive marker of acute inflammatory
reactions. High plasma levels of this protein are associated
with a future risk of cardiovascular events. CRP is therefore
considered to be an independent risk factor for the
development of this type of disease (18). The levels of
CRP are higher in apparently healthy women using HT.
Certain authors believe that estrogen therapy may stimulate
and/or aggravate an inflammatory process that, in predis-
posed women, could contribute to the progression to
atherosclerosis and the thrombotic process (19). However,
this effect is not clear for unopposed estrogen (20).
Therefore, the aim of this study was to evaluate the effects
of estrogen therapy and estrogen-progestin therapy on
homocysteine and CRP levels in postmenopausal women.
& METHODS
A total of 242 postmenopausal women (last natural
menstruation at least 12 months prior to entering the study)
were evaluated between December 2, 2000 and January 31,
2002. Of these women, 99 were selected for enrollment into
this study. To be considered for inclusion in this study, the
women had to have vasomotor complaints (based on the
Kupperman Menopausal Index), should not have had a
hysterectomy and should not have been using HT in the 60
days preceding admission to the study.
The exclusion criteria consisted of women with a body
mass index $35, those who were taking vitamin supple-
ments (vitamin B6, vitamin B12 and/or folic acid), those
who engaged in physical exercise (with the exception of
light walks fewer than three times per week), those who had
an endometrial thickness.5 mm according to ultrasonogra-
phy carried out within the previous six months, those who
had any abnormality detected by recent mammography or
cervicovaginal oncological colpocytology (carried out in the
previous 12 months) and those who presented a personal
history of cardiovascular disease or venous or arterial
thromboembolism. Women presenting dyslipidemia, dia-
betes mellitus, or acute or chronic hepatopathies were also
excluded as well as those using cholesterol-reducing
medication, androgens, raloxifene, tamoxifen, barbiturates,
hydantoin, carbamazepine, phenylbutazone, meprobamate
or rifampicin and those with hormone-dependent cancer.
All subjects voluntarily agreed to participate in the study,
which was approved by the institution’s Ethics Committee
in Research and all patients signed informed consent forms.
This longitudinal clinical trial was a prospective, rando-
mized, double-blind, placebo-controlled study. A total of 99
patients were randomly distributed into three different
groups (33 in each): Group A received unopposed estrogen
therapy (2.0 mg of 17 b-estradiol), Group B was treated with
an estrogen-progestin combination (2.0 mg of 17 b-estradiol
+1.0 mg of norethisterone acetate) and Group C received
pills containing no active substance (placebo).
Prior to the initiation of treatment, all patients were
subjected to general physical and gynecological examina-
tions and their medical history was recorded. The climac-
teric symptoms were evaluated using the Kupperman
Menopausal Index. Blood samples were collected from all
patients in the morning, following a 12-hour fast, both at
baseline and after six months of treatment for the measure-
ment of the serum levels of homocysteine and CRP
(Laborato´rio Central, UNIFESP, Sa˜o Paulo, Brazil). The
blood sampling was carried out at a maximum of 15 days
prior to the initiation of therapy and at the end of six months
of treatment.
The Kupperman index is a numerical conversion index
that covers 11 menopausal symptoms: hot flushes (vaso-
motor), paresthesia, insomnia, nervousness, melancholia,
vertigo, weakness, arthralgia or myalgia, headache, palpita-
tions and stinging. Each symptom in the Kupperman index
is rated on a scale from 0 to 3 for no, slight, moderate and
severe complaints. To calculate the Kupperman index (21),
the symptoms are weighted as follows: hot flushes (x4),
paresthesias (x2), insomnia (x2), nervousness (x2) and all
other symptoms (x1). The highest potential score is thus 51.
The score for hot flushes was based on the number of
complaints per day: slight (more than 5), moderate (5-10), or
severe (more than 10).
Homocysteine was measured by high-performance liquid
chromatography (HPLC) using a C-R4A Chromatopac
Integrator (SHIMADZU), an R-F-10AXL Fluorescent Detector
(SHIMADZU), an LC-10AD Pump (SHIMADZU) and a 234
Autoinjector (GILSON). For this method, an intra-test
variation level of 4.5% was considered acceptable. Serum
CRP was measured by nephelometry using an Array 360
System (Beckman Coulter) with an intra-test variation level
established at 5.0%.
Each patient completed four visits (V) during the study:
V0, at day 0; V1, 7¡3 days after V0; V2, 90¡5 days after V1;
and V3, 90¡5 days after V2.
Statistical analysis
The characteristics of the groups were analyzed by one-
way repeated-measures analysis of variance subsequently
corrected by a least-significant-difference comparison test
(Fisher test). The statistical analysis of the homocysteine and
CRP data was based on a non-parametric method and the
Kruskal-Wallis test was used to compare the three groups
in the study. The rejection of the null hypothesis was
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established at 5% (p#0.05). The Dunn test was applied to
identify differences between the initial and the final
measurements of the serum levels of homocysteine and
CRP in each group. The Wilcox test was used to detect any
evidence that the variable in question had undergone a
change between the beginning and the end of the evaluation
period. The results of the Dunn test were used to compare
the absolute differences between the means of each pair of
groups.
& RESULTS
Of a total of 99 women who began this study, 12
discontinued their participation prior to study completion,
with 3 in Group A, 2 in Group B and 7 in Group C. In Group
A, the three discontinuations occurred due to mastalgia,
irregular bleeding and loss to follow-up. Irregular bleeding
was the cause of discontinuation for the two patients in
Group B. Of the patients in Group C, three abandoned the
study because they felt no improvement in vasomotor
symptoms, one because of mastalgia, one because of an
acute myocardial infarction, one because of a carotid
obstruction and one because of loss to follow-up.
At the two evaluative visits (during the 3rd and 6th
months), the number of tablets returned to the clinic was
proportional to the number of days remaining until the end
of treatment in all cases, indicating that compliance was
similar in the three groups.
Data on the patient characteristics are shown in Table 1.
The statistical analyses showed no difference between the
groups for any of the parameters: age, the time since
menopause, body mass index, the Kupperman Menopausal
Index, systolic blood pressure, diastolic blood pressure and
smoking. All participants had normal levels of glucose and
no history of diabetes.
Table 2 and Figure 1 show the distribution of the basal
homocysteine and CRP measurements. There were no
statistically significant differences in the basal values of
these markers between any of the three groups in the study.
Additionally, the table shows the percentage of variation in
homocysteine levels in the three groups following six
months of treatment. A mean reduction of 20.7% was
observed in Group A when these levels were compared
with basal values (p,0.01). In Group B, there was also a
significant reduction (12.2%) when compared with initial
values (p,0.01). In Group C, there was a mean increase of
16.5% relative to basal measurements, which was not
statistically significant.
When the entire sample was examined, the distribution of
homocysteine was found to vary between the 3 groups
(p,0.01). Dunn’s test, applied posteriorly, indicated statis-
tically significant differences between Groups A and C and
between Groups B and C but not between the patients
receiving estrogen therapy and those receiving estrogen-
progestin therapy (Groups A and B, respectively). At the
end of treatment, homocysteine levels were significantly
lower (p,0.01) in the groups using hormones compared
with the placebo group.
The levels of CRP increased in all groups following six
months of therapy (Table 2 and Figure 2), but this increase
only reached statistical significance in the two groups
receiving active medication (estrogen alone or associated
with progestin). In Groups A and B, there were increases of
100.5% (p,0.01) and 93.5% (p,0.01), respectively. These
values showed statistical significance in relation to the value
in the placebo group but were not significantly different from
each other. When the sample was considered as a whole, there
was evidence that the distribution of CRP showed certain
differences between the three groups (p,0.01). Dunn’s test,
applied posteriorly, showed statistically significant differ-
ences between Groups A and C and between Groups B and C.
& DISCUSSION
Postmenopausal women have higher blood levels of
homocysteine compared with younger women (22).
Certain studies have shown that HT is able to significantly
reduce these levels. Van der Mooren et al. (23) reported a
significant reduction in homocysteine levels following six
months of oral sequential combined therapy. Moreover,
these reduced levels remained stable during the 24 months
of treatment. Twelve months after the end of this therapy,
homocysteine levels increased, i.e., they returned to pre-
treatment levels. Mijatovic et al. (24) followed 135 healthy
women who were using oral continuous combined estro-
gen-progestin therapy. The authors reported a significant
reduction (13.5%) in homocysteine levels following six
Table 1 - Characteristics of the participants (mean ¡
standard deviation) in all groups at baseline: A
(unopposed estrogen), B (estrogen-progestin
combination) and C (placebo).
Group A (n=30) B (n= 31) C (n= 24)
Age (years) 50.2¡1.2 51.3¡1.2 51.1¡1.8
Time since menopause (years) 3.7¡1.5 3.8¡1.7 4.1¡1.1
Body mass index (Kg/m2) 25.4¡1.1 27.3¡1.7 26.4¡1.6
Kupperman Menopausal Index 31.8¡1.2 33.8¡2.2 32.8¡2.1
Systolic blood pressure (mmHg) 122.1¡13.9 123.1¡15.4 118.1¡15.1
Diastolic blood pressure (mmHg) 81.7¡10.9 82.6¡14.3 83.9¡11.3
Smokers (n) 3 4 3
The statistical analyses showed no differences between the groups for any
parameter.
Table 2 - Homocysteine (mmol/l) and C-reactive protein (ng/l) levels of the participants during the study.
Group A (unopposed estrogen, n = 30)
B (estrogen-progestin
combination, n= 31) C (placebo, n= 24)
baseline after* D baseline after* D baseline after* D
Homocysteine (mmol/l) 8.8¡3.5 6.9¡2.5a - 21.6¡- 29.8b 9.6¡3.4 8.4¡3.1a - 12.2¡- 28.9c 9.7¡3.4 11.3¡5.3 16.5¡55.1
C-reactive protein (mg/l) 3.0¡2.0 6.0¡5.5a 100.5¡127.1 b 3.1¡2.2 5.9¡4.3 a 93.5¡96.4c 3.2¡1.4 4.0¡2.1 a 25.5¡48.9
*After six months of treatment; D= [(value after treatment - baseline value)/baseline value * 100]. The statistical analyses showed no difference between
the groups’ baseline homocysteine and C-reactive protein levels; a – p,0.01 compared with baseline (Wilcox test); b – p,0.01 compared with D of the
other groups (Kruskal-Wallis and Dunn tests); c – p,0.01 compared with D of Group C (Kruskal-Wallis and Dunn tests).
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months of treatment. The greatest reduction occurred in
those who presented the highest pretreatment levels.
Madsen et al. (25) carried out a study in 209 postmenopau-
sal women and showed that homocysteine levels decreased
significantly after five years of follow-up in those women
using estrogen or estrogen-progestin therapy. Regardless of
the estrogen regimen, HT may reduce homocysteine levels.
In our study, we observed a 20.7% reduction in homo-
cysteine levels in women using estrogen therapy after six
months of treatment compared with a 12.2% reduction in
those using estrogen-progestin therapy. In the women who
were taking a placebo, there was an increase of 16.5%.
Therefore, estrogen was better at reducing homocysteine
levels than combined steroids were. However, another
Figure 1 - Graphical representation of homocysteine values during the study: a) baseline; b) after six months of treatment; c) delta {(D=
[(value after treatment - baseline value)/baseline value * 100]}. *p,0.01 compared with the other groups; **p,0.01 compared with the
placebo group.
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study found a similar difference between the two estrogen
regimens (unopposed and combined) (26).
The mechanism through which hyperhomocysteinemia
predisposes an individual to atherogenesis and thrombogen-
esis is still not fully understood. However, it appears that
increased levels of homocysteine cause a predisposition to
endothelial injury, stimulate HDL oxidation through an
increase in the activity of the methionine synthetase enzyme
and affect the proliferation of the endothelial smooth muscle
cells (15-17). As a result, 1 mmol/L and 3 mmol/L reductions
in the plasma levels of homocysteine are associated with
reductions of 10% and 30%, respectively, in the risk of
cardiovascular disease (27). The greatest reduction in the levels
of this substance was found in the estrogen group in our study.
The relationship between HT and inflammatory response
markers, such as CRP, has been widely discussed. In the
CARE study, Ridket et al. (28) showed that individuals at
greater risk of developing cardiovascular disease had higher
Figure 2 - Graphical representation of C-reactive protein values during the study: a) baseline; b) after six months of treatment; c) delta
{(D= [(value after treatment - baseline value)/baseline value * 100]}. *p,0.01 compared with the other groups; **p,0.01 compared
with the placebo group.
CLINICS 2015;70(2):107-113 HT’s Effect on Homocysteine and CRP Levels
Lakryc EM et al.
111
basal levels of CRP. It is important to emphasize that the
baseline CRP levels may be associated with an increased
risk of clinical problems (28-31). In our study, many patients
presented high levels of CRP. Increased levels of CRP are
also found in users of HT. Estrogen therapy and estrogen-
progestin therapy both appear to stimulate or aggravate an
inflammatory process in the endothelium that contributes to
the progression to arteriosclerosis and the activation of the
coagulation system in high-risk women (29). Evidence
indicates that the administration of estrogens may stimulate
a pro-inflammatory effect appearing at the beginning of
therapy and reverting immediately following the cessation
of treatment. However, this phenomenon may be associated
with a first-pass hepatic effect rather than a pro-inflamma-
tory response (30-33).
It appears that the increased hepatic production of CRP is
related to the oral administration of HT. In this respect,
Sattar et al. (34) found a significant reduction in CRP levels
following the transdermal use of 17-b-estradiol combined
with norethisterone acetate compared with levels in the
placebo group. Bukowka et al. reported 61% and 39%
increases in CRP levels in the users of oral and transdermal
HT, respectively, after three months of therapy (35).
In a study of 493 postmenopausal women, Ridker et al.
(36) showed that CRP levels increased two-fold in those
patients who were using estrogen or estrogen-progestin
therapy compared with the control group. Moreover, in a
re-analysis of the PEPI trial, it was shown that the patients
using HT presented an increase in CRP levels. The CRP
levels in these patients were 85% higher than those in the
placebo group (37). In our study, the mean increases in the
levels of CRP after six months of treatment were 100.5% in
patients who were taking isolated estrogens, 93.5% in those
taking a combination of estrogen and progestin, and 25.5%
in the control group. In a recent study, Kwang et al. (38)
reported a 70% increase in CRP levels in women using
conjugated equine estrogens at 0.625 mg/day after six
months of treatment. In the same study, when simvastatin
was added to the treatment, the increase in CRP levels was
lower (29%). However, in the group of women who were
taking only the cholesterol-reducing medication at a dose of
10 mg daily, no change was recorded in CRP levels.
Therefore, HT may influence simvastatin’s effect.
Another feature of our study was the age of the
participants. Certain investigators have suggested a life
period called a ‘‘window of opportunity’’ for HT after
menopause. In fact, the cardiovascular risk may be low if
estrogen or estrogen-progestin therapy is started during this
period, in which the time since menopause must be less than
10 years and the age of the woman must not be greater than 60
years old (39). All participants in our study had these features,
which may have influenced our results. Regardless of the CRP
results, our data suggested that HT and mainly unopposed
estrogen, may have a positive effect on the cardiovascular
system due to a significant reduction in homocysteine levels.
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